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Estrogen protects bone by inducing Fas ligand
in osteoblasts to regulate osteoclast survival
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Estrogen deﬁciency in menopause is a major cause of
osteoporosis in women. Estrogen acts to maintain the
appropriate ratio between bone-forming osteoblasts and
bone-resorbing osteoclasts in part through the induction
of osteoclast apoptosis. Recent studies have suggested a
role for Fas ligand (FasL) in estrogen-induced osteoclast
apoptosis by an autocrine mechanism involving osteo-
clasts alone. In contrast, we describe a paracrine mechan-
ism in which estrogen affects osteoclast survival through
the upregulation of FasL in osteoblasts (and not osteo-
clasts) leading to the apoptosis of pre-osteoclasts. We
have characterized a cell-type-speciﬁc hormone-inducible
enhancer located 86kb downstream of the FasL gene as
the target of estrogen receptor-alpha induction of FasL
expression in osteoblasts. In addition, tamoxifen and
raloxifene, two selective estrogen receptor modulators
that have protective effects in bone, induce apoptosis
in pre-osteoclasts by the same osteoblast-dependent
mechanism. These results demonstrate that estrogen pro-
tects bone by inducing a paracrine signal originating in
osteoblasts leading to the death of pre-osteoclasts and offer
an important new target for the prevention and treatment
of osteoporosis.
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Introduction
Estrogen is an important regulator of female development,
and also plays a role in the brain (Cutter et al, 2003),
skin (Kanda and Watanabe, 2004), liver (Srivastava et al,
1997), hair (Ohnemus et al, 2005), adipocytes (Cooke and
Naaz, 2004), immune system (Cutolo et al, 2004) and bone
(Rickard et al, 1999), among other tissues. The effects of
estrogen are mediated by two nuclear receptors: estrogen
receptor alpha (ERa) and estrogen receptor beta (ERb).
ERa and ERb are both expressed in many cell types, but at
lower levels than those found in reproductive tissues
(Zallone, 2006).
Low circulating estrogen is an important risk factor for
post-menopausal osteoporosis (Sambrook and Cooper, 2006).
Estrogen and ERs are important for bone formation in
humans (Smith et al, 1994) and mice (Windahl et al, 2002).
Furthermore, decreased estrogen levels due to natural or
surgically induced menopause lower bone mineral density
in humans (Eastell, 2006) and rodents (Wronski et al, 1989).
Women who are at risk for osteoporosis are treated currently
with estrogen replacement therapy, selective estrogen
receptor modulators (SERMs) or bisphosphonates.
Estrogen has been shown to induce apoptosis in bone-
resorbing osteoclasts (Kameda et al, 1997; Kousteni et al,
2002). Furthermore, estrogen is anti-apoptotic in osteoblasts,
leading to an overall building of bone (Kousteni et al, 2002).
ER knockout (ERKO) mice have an increase in the total
number of osteoclasts due to the lack of estrogen-induced
osteoclast apoptosis (Parikka et al, 2005). A recent study by
Nakamura et al (2007), using osteoclast-speciﬁc ERa knock-
out mice suggested that ERa expression in osteoclasts
was necessary for their apoptosis. In addition, these authors
suggested an autocrine mechanism for the estrogen-induced
apoptosis of osteoclasts involving the induction of Fas ligand
(FasL) in these same cells.
To gain a better understanding of the mechanism by which
estrogen induces FasL in bone leading to osteoclast apoptosis,
we studied the effects of estrogen (and SERMs) on mouse and
human osteoclast differentiation and survival in vitro and in
vivo and on the expression of FasL in both osteoclasts and
osteoblasts. In contrast to previous studies, we ﬁnd that the
induction of apoptosis by estrogen occurs at the pre-osteo-
clast stage of osteoclast development and that this requires
the presence of osteoblasts and the estrogen induction of FasL
expression in osteoblasts and not osteoclasts.
Results
Regulation of the development of mature osteoclasts by
estradiol
Osteoclasts are derived from hematopoietic stem cells
(Walker, 1975) differentiating from myeloid precursors
in the presence of receptor activator of NF-kB ligand
(RANKL) and macrophage colony-stimulating factor
Received: 24 October 2007; accepted: 19 December 2007; published
online: 24 January 2008
*Corresponding author. Division of Molecular and Cellular Oncology,
Department of Medical Oncology, Dana-Farber Cancer Institute,
44 Binney Street, D730, Boston, MA 02115, USA.
Tel.: þ1 617 632 3948; Fax: þ1 617 632 5417;
E-mail: myles_brown@dfci.harvard.edu
5Present address: Cancer Research UK, Cambridge Research Institute,
Robinson Way, Cambridge CB2 0RE, UK
The EMBO Journal (2008) 27, 535–545 | & 2008 European Molecular Biology Organization|All Rights Reserved 0261-4189/08
www.embojournal.org
&2008 European Molecular Biology Organization The EMBO Journal VOL 27 | NO 3 | 2008
 
EMBO
 
THE
EMBO
JOURNAL
THE
EMBO
JOURNAL
535(M-CSF) (Boyle et al, 2003). Pre-osteoclasts, or mononuclear
osteoclasts, are deﬁned as mononuclear cells that stain
positive for tartrate-resistant acid phosphatase (TRAP) and
express cathepsin K mRNA (Supplementary Figure 1)
(Hershey and Fisher, 2004). Fully differentiated osteoclasts
are multinucleated, TRAP positive, and have increased ex-
pression of cathepsin K and calcitonin receptor mRNA
(Supplementary Figure 1). To determine the effect of estrogen
on osteoclast differentiation and survival, bone marrow cells
were obtained from BALB/c mice and differentiated with
RANKL and M-CSF in the presence or absence of 17b-
estradiol (E2) for 8 days (Figure 1A). The majority of cells
in these cultures are of the myeloid lineage; however, a small
percentage of the surviving cells after 8 days in this culture
system are of mesenchymal origin, including osteoblasts (see
below). E2 inhibited, in a dose-dependent manner, mature
osteoclast formation. As little as 0.1nM E2 prevented the
appearance of multinuclear osteoclasts. Treatment with
10nM E2 caused death in most cells, and those remaining
did not stain positive for TRAP. In addition, pre-osteoclasts
treated with E2 for 6 days had decreased cathepsin K and
calcitonin receptor mRNA levels (Figure 1B and C), support-
ing the conclusion that E2 inhibited mature osteoclast
formation. A 3h exposure to E2 in pre-osteoclasts or osteo-
clasts had no effect on cathepsin K mRNA (data not shown).
It has been previously demonstrated that estrogen induces
apoptosis of osteoclasts, but its mechanism has not been fully
elucidated (Kameda et al, 1997; Kousteni et al, 2002). In
particular, the possibility that a small number of osteoblasts
present in osteoclast cultures might be playing a role was not
examined. To determine at what stage in osteoclast differ-
entiation estrogen induces apoptosis, the effect of E2 was
tested in pre-osteoclasts and fully differentiated osteoclasts.
Apoptosis occurred in the TRAP-positive pre-osteoclasts
(Figure 1D). This supports data by Sorensen et al (2006)
that estrogen has no effect on the resorption or TRAP activity
of mature osteoclasts. We then investigated the concentration
and duration of estrogen treatment required for apoptosis.
After 7h of 1nM E2 treatment, approximately 10% of pre-
osteoclasts were apoptotic, as measured by the TUNEL assay,
and 10nM E2 treatment induced apoptosis in 25% of pre-
osteoclasts (Figure 1D and Supplementary Figure 2). After
24h of treatment with 10nM E2, nearly 100% of cells were
TUNEL positive (Figure 1D). Taken together, the data illus-
trate that E2 can block the formation of mature osteoclasts by
inducing death at the pre-osteoclast stage.
Figure 1 Estrogen induces apoptosis in pre-osteoclasts and prevents the formation of mature osteoclasts. (A) Bone marrow was differentiated
with M-CSF and RANKL for 8 days in the presence of ethanol (EtOH), 0.1nM estradiol (E2), 1nM E2 or 10nM E2. Cells were then ﬁxed and
stained for TRAP. (B) The expression of cathepsin K mRNA or (C) calcitonin receptor mRNAwas measured by quantitative real-time PCR from
RNA isolated from bone marrow, pre-osteoclast and osteoclast cultures treated with or without 10nM E2 for the entire course of differentiation.
Fully differentiated osteoclasts treated with E2 were never formed and thus there is no value in this ﬁgure. The fold induction was normalized
to b-actin mRNA. Error bars represent 71 s.d. (D) Bone marrow was differentiated to the pre-osteoclast or osteoclast state with M-CSF and
RANKL and then treated for 7 or 24h with vehicle (EtOH), 1nM E2 or 10nM E2. Cells were ﬁxed and apoptosis was detected by TUNEL.
Quantiﬁcation was performed using a laser scanning cytometer. Data are representative of three independent experiments.
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A recent paper by Nakamura et al (2007) suggests that
estrogen induces FasL in osteoclasts to induce apoptosis in
an autocrine manner. To verify that Fas and FasL were
activated upon treatment with estrogen, E2-induced apopto-
sis of pre-osteoclasts was quantiﬁed in the presence or
absence of a FasL neutralizing antibody. E2-mediated
apoptosis was blocked in the presence of a neutralizing
FasL antibody, conﬁrming that E2-mediated apoptosis of
pre-osteoclasts is FasL dependent (Figure 2A and Supple-
mentary Figure 3).
To further verify that estrogen-mediated apoptosis occurs
through the Fas/FasL pathway, pre-osteoclasts were differen-
tiated from the bone marrow from FasL-deﬁcient mice (gld)
and Fas-deﬁcient mice (lpr). Mice carrying either the gld or
the lpr mutation suffer from lymphadenopathy and auto-
immune disease due to the loss-of-function point mutations
in FasL and Fas (Cohen and Eisenberg, 1991; Takahashi et al,
1994). Bone marrow-derived cells from gld and lpr mice were
differentiated to the pre-osteoclast stage, and then treated
with 10nM E2 for 16h. Whereas pre-osteoclasts from wild-
type mice were apoptotic after E2 treatment, pre-osteoclasts
from FasL- and Fas-deﬁcient mice failed to undergo apoptosis
(Figure 2B). This provides genetic evidence that the Fas/FasL
pathway is necessary for estrogen-induced apoptosis of
pre-osteoclasts.
To determine if the Fas/FasL pathway is transcriptionally
activated by E2 in osteoclasts, we analyzed both Fas and FasL
mRNA levels. RNA was obtained from bone marrow stroma,
pre-osteoclasts and osteoclasts, and Fas mRNA levels were
measured by quantitative real-time PCR and compared to the
level in the thymus as a positive control. Detectable levels of
Fas were found in pre-osteoclasts; however, Fas mRNA did
not increase after E2 treatment of pre-osteoclasts or osteo-
clasts (Figure 2C). Likewise, FasL mRNA levels were deter-
mined by quantitative real-time PCR in pre-osteoclasts and
osteoclasts, and the levels of FasL were also not increased by
E2 in these cells (Figure 2D). Thus while Fas/FasL signaling is
required for the E2-induced apoptosis of pre-osteoclasts, the
levels of neither were directly regulated by E2 in this cell type.
Estrogen induces FasL transcription in osteoblasts
As we could ﬁnd no evidence for the estrogen regulation of
Fas or FasL in osteoclasts, we hypothesized that a second
bone cell type, namely osteoblasts, might play a role in the
induction of apoptosis in osteoclasts. To this end, osteoblasts
were tested for the induction of FasL mRNA. Primary cal-
varial osteoblasts were obtained from neonatal mice.
Throughout the differentiation process of osteoblasts, E2
increased the levels of FasL mRNA in these cells. E2 increased
FasL mRNA by approximately three-fold early in differentia-
tion and by ﬁve-fold in fully differentiated osteoblasts
(Figure 3A). This result was conﬁrmed in the mouse calvarial
pre-osteoblast cell line MC3T3 that was differentiated into
mature osteoblasts by treatment with ascorbic acid for 10
days. In differentiated MC3T3 cells, FasL mRNA levels
increased three-fold in the presence of E2 (Figure 3E).
To further characterize the regulation of FasL by E2, the
osteoblast-like U20S-ERa cell line and control MCF-7 breast
cancer cell line were also treated with E2 to determine if FasL
levels were increased. The U20S-ERa cell line is an osteosar-
coma cell line that was stably transfected with doxycycline-
inducible expression of ERa. Upon treatment with doxycy-
cline, the expression of ERa in U20S-ERa cells is similar to
MCF-7 cells (Monroe et al, 2003). Whereas MCF-7 cells had
no detectable levels of FasL by quantitative real-time PCR, E2
increased the mRNA levels of FasL in the U20S-ERa cell line
(Figure 3B), indicating that E2 induction of FasL is osteoblast
speciﬁc.
To understand the mechanism by which estrogen speciﬁ-
cally upregulates FasL mRNA in osteoblasts, we sought to
identify whether FasL is a direct ERa target gene. Our
previous work deﬁning authentic ERa binding sites across
the whole human genome in MCF-7 cells by chromatin
immunoprecipitation (ChIP) on whole genome tiling arrays
(Carroll et al, 2006) identiﬁed a potential site near the FasL
gene. This binding site, located 86 kilobases (þ86kb)
telomeric of the FasL coding region, contains a well-con-
served estrogen response element (Supplementary Figure 4).
We have previously shown that ER binding sites are often
distant and downstream of the transcription start sites of
target genes (Carroll et al, 2005). In addition, the nearest gene
telomeric to this ERa binding site is TNFSF18, which is 265kb
away from the site and is not regulated by E2 in U20S-ERa
Figure 2 Estrogen-induced apoptosis is mediated by the Fas/FasL
pathway. (A) Pre-osteoclasts were differentiated with M-CSF and
RANKL for 6 days and then treated for 16h with vehicle (EtOH) or
10nM E2, and either a control IgG or 5pg/ml FasL neutralizing
antibody. Cells were ﬁxed and apoptosis was detected by TUNEL.
Quantiﬁcation was performed using a laser scanning cytometer.
Data are representative of three independent experiments. (B) Pre-
osteoclasts from wild-type, FasL-deﬁcient mice (gld) and Fas-deﬁ-
cient mice (lpr) were differentiated with M-CSF and RANKL for 6
days and then treated for 16h with vehicle control (EtOH) or 10nM
E2. Cells were ﬁxed and apoptosis was detected by TUNEL.
Quantiﬁcation was performed using a laser scanning cytometer.
(C) Fas and (D) FasL mRNA levels were analyzed by quantitative
PCR from RNA obtained from bone marrow stroma (BM stroma),
pre-osteoclasts (pre-OC) with and without 10nM E2, osteoclasts
with and without 10nM E2 and thymus.
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shown). To test whether the ERa binding site 86kb down-
stream of the FasL transcription start site was bound in
osteoblast-like cells, we conducted directed ChIP for ERa
in MCF-7 and U20S-ERa cells. As predicted from our previous
study, ERa levels were enriched at the þ86kb site in MCF-7
cells. Strikingly, both the basal and E2-induced binding levels
were very signiﬁcantly greater in U20S-ERa cells compared to
MCF-7 (Figure 3C). Although there is recruitment of ERa
to this region in MCF-7 cells, recruitment of ERa to DNA is in
many cases not sufﬁcient for gene activation (Carroll et al,
2006). Consistent with the pattern of FasL gene expression,
RNA polymerase II is not recruited to the promoter of FasL in
MCF-7 cells, but it is recruited in U20S-ERa cells following
estrogen stimulation (Figure 3D).
To conﬁrm that ERa is recruited to the putative FasL
enhancer in osteoblasts, we performed directed ChIP in the
MC3T3 cells that had been differentiated for 10 days with
ascorbic acid. ERa was detectable at the FasL enhancer,
increasing almost two-fold after treatment with E2
(Figure 3F). These results support the conclusion that FasL
is a direct ERa target gene in osteoblasts and that this
regulation involves a cell-type-speciﬁc estrogen-stimulated
enhancer located 86kb downstream of the FasL coding
region.
FasL is induced in osteoblasts by E2 in vitro
To determine which cells express Fas and FasL in the mixed
bone cell cultures, murine bone marrow cells were differen-
tiated with RANKL and M-CSF, and then the cells were ﬁxed
and immunostained. First, osteoblasts were identiﬁed by
alkaline phosphatase staining (Figure 4A) and then co-
stained for Fas. The osteoblasts did not stain positive for
Fas, but all of the remaining cells were positive for Fas. In
Figure 3 Estrogen increases FasL in osteoblasts. (A) Primary calvarial osteoblasts were differentiated for 3, 5 or 13 days in the presence of
100 mg/ml ascorbic acid and 5mM b-glycerophosphate. Cells were then treated with 10nM E2 for 3h and RNA was obtained. FasL mRNA was
analyzed by quantitative PCR. (B) U20S-ERa and MCF-7 cells were deprived of estrogen for 3 days in phenol red-free media containing 5% CDT-
FBS. They were then treated with 10nM E2 for 0, 3, 6 or 12h and RNAwas obtained. FasL mRNAwas analyzed by quantitative PCR. (C) U20S-
ERa cells and MCF-7 cells were deprived of estrogen for 3 days in phenol red-free media containing 5% CDT-FBS. They were then treated with
10nM E2 for 45min. ERa (C) and RNA polymerase II (RNA Pol II) (D) were immunoprecipitated, DNAwas isolated and quantitative PCR was
performed at the indicated sites of the FasL locus. Each PCR signal was normalized to input. (E) MC3T3 cells were differentiated for 10 days in
the presence of 100mg/ml ascorbic acid. The media were then changed to phenol red-free media containing 5% CDT-FBS for 3 days. The cells
were then treated with 10nM E2 for 3h and FasL mRNA was analyzed by quantitative PCR. (F) MC3T3 cells were differentiated for 10 days in
the presence of 100mg/ml ascorbic acid. The media were then changed to phenol red-free media containing 5% CDT-FBS for 3 days. The cells
were then treated with 10nM E2 for 45min. ERa was immunoprecipitated, DNAwas isolated and quantitative PCR was performed with primers
for the FasL enhancer. Each PCR signal was normalized to input. Error bars in all panels represent 71s . d .
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of the osteoclast adjacent to neighboring osteoblasts, indica-
tive of Fas activation (Figure 4A, inset).
Second, to characterize FasL-expressing cells, bone
marrow cells were differentiated with RANKL and M-CSF
and immunostained with antibodies to FasL and RUNX2.
Immunoﬂuorescent microscopy showed that the majority of
the cells are positive for 40,6-diamidino-2-phenylindole
(DAPI) only (Figure 4B). Osteoblast cells, marked by the
expression of RUNX2, were also positive for FasL
(Figure 4B). We performed laser scanning cytometry (LSC)
analysis on these samples to quantify the percentage of cells
that were positive for RUNX2 and/or FasL in the presence or
absence of 10nM E2. The data indicate that only 3% of the
total cells are osteoblasts and the amount of RUNX2 did not
change in the presence of E2 (Supplementary Figure 5).
When we determined the number of RUNX2/FasL double
positive cells, 17% of the untreated osteoblasts were positive
for RUNX2 and FasL. Upon treatment with E2, 35% of the
osteoblasts were positive for both RUNX2 and FasL
(Figure 4C), suggesting that in mixed bone cultures in vitro,
osteoblasts and not osteoclasts are the cells in which FasL is
expressed and estrogen-regulated.
FasL is induced by E2 in vivo
In order to conﬁrm that estrogen activates FasL in osteoblasts
in vivo, sham-operated and ovariectomized mice were treated
with vehicle or 50mg/kg body weight of E2 for 24h. Femurs
from ovariectomized mice had signiﬁcantly higher TRAP
staining (Supplementary Figure 6) than in sham-operated
mice, indicating an increase in the number of osteoclasts
due to the absence of estrogen and lack of estrogen-induced
apoptosis. FasL was localized by immunohistochemisty
before and after treatment with E2. FasL was not observed
in the femurs from untreated animals, but FasL could be
identiﬁed at the endosteal surface (Figure 5A and C) and at
the growth plate (Figure 5B) in femurs from E2-treated mice.
To directly conﬁrm that FasL-positive cells were indeed
osteoblasts, immunoﬂuorescence for the osteoblast-speciﬁc
RUNX2 and FasL was performed on femurs from control and
E2-treated mice. Osteoblasts (identiﬁed by RUNX2 staining)
from vehicle-treated mice were negative for FasL (Figure 5D).
After treatment with E2, FasL-positive staining was visualized
in osteoblasts (Figure 5E). Furthermore, these FasL-positive
osteoblasts were next to TRAP-positive osteoclasts at both the
growth plate (Figure 5B) and in the diaphysis (Figure 5C).
Apoptosis of osteoclasts by estradiol is mediated
by ERa
To test whether E2-induced apoptosis was mediated by
nuclear ERs, mixed bone marrow cultures were differentiated
with M-CSF and RANKL for 6 days, followed by treatment
with E2 and the pure ER-antagonist fulvestrant (ICI), alone or
in combination. Fulvestrant alone did not cause apoptosis of
pre-osteoclasts, but it was able to block E2-mediated
apoptosis, indicating involvement of the classical nuclear
ER pathway (Figure 6A).
To determine the contribution of ERa versus ERb in
E2-induced apoptosis, bone marrow was obtained from ERa
knockout (ERaKO), ERb knockout (ERbKO) and ERa/ERb
double knockout (ERabKO) mice. Bone marrow cells from
wild-type, ERaKO, ERbKO and ERabKO mice all formed
Figure 4 Fas is expressed in pre-osteoclasts and FasL is expressed in osteoblasts. (A) Bone marrow cultures treated under osteoclastic
conditions for 6 days to the pre-osteoclast stage were ﬁxed and immunostained for Fas. The primary antibody was detected with an anti-rabbit
IgG Alexa 488 (green ﬂuorescence). DNAwas counterstained with DAPI. The cells were then stained for alkaline phosphatase (dark blue cells).
The red arrowhead points to clustering of the Fas receptor proteins next to the osteoblast. Parallel cultures were stained with TRAP to identify
pre-osteoclasts. (B) Bone marrow cultures treated under osteoclastic conditions for 6 days to the pre-osteoclast stage were ﬁxed and
immunostained for FasL and RUNX2. DNA was counterstained with DAPI. (C) A laser scanning cytometer was used to separate cells with low
and high RUNX2. The amount of FasL in the presence or absence of 10nM E2 was quantiﬁed in each of these populations.
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osteoclasts from wild-type C57BL/6 mice and ERbKO mice
were TUNEL positive after a 16h exposure to E2. However,
ERaKO (and ERabKO) osteoclasts failed to undergo apoptosis
when treated with 10nM E2 (Figure 6B and Supplementary
Figure 7). As a result, there were as many TRAP-positive,
multinucleated osteoclasts in ERaKO cultures treated with
E2 as in vehicle control-treated cultures (Figure 6C).
As E2 induces FasL via ERa, we hypothesized that FasL
levels would be lower in osteoblasts from ERaKO mice. Bone
marrow cells were cultured in mesenchymal stem cell media
and then differentiated to osteoblasts with ascorbic acid and
b-glycerophosphate. The FasL mRNA levels were 10-fold
lower in ERaKO cells when compared to the wild-type
osteoblasts (Figure 6D).
To further conﬁrm that activation of ERb did not play a role in
pre-osteoclast apoptosis, we tested for the induction of FasL in
U20S-ERb cells. The U20S-ERb cell line, like the U20S-ERa cell
line, is derived from the parental U20S cells, but it is stably
transfected with doxycycline-inducible ERb cDNA. Whereas E2
led to the induction of FasL in U20S-ERa cells (Figure 3B), FasL
mRNA was unchanged in the U20S-ERb cells (Figure 6E), while
a positive control ERb target gene, retinoblastoma binding
protein 1 (Rbbp1), (Monroe et al, 2006) was induced by ERb
in the presence of E2 (Figure 6E). Consistent with the expression
results, E2 did not induce recruitment of ERb to the þ86kb ERa
binding site (Figure 6F). The Rbbp1 enhancer was used as a
positive control for ERb binding (Monroe et al, 2006). Taken
together, these data demonstrate that E2 mediates osteoblast-
dependent pre-osteoclast apoptosis via ERa and not ERb.
Figure 5 FasL is induced by E2 in osteoblasts in vivo.( A) Ovariectomized mice were treated with either vehicle (veh.) or 50mg/kg E2 for 24h.
Parafﬁn-imbedded femurs were immunostained with an antibody to FasL (blue) and the sections were counterstained with hematoxylin (pink).
BM¼bone marrow, CB¼cortical bone. (B) The growth plate and (C) diaphysis of E2-treated femurs were immunostained with FasL (blue) and
osteoclasts were identiﬁed with TRAP (pink). HC¼hypertrophic chondrocytes. The cells were counterstained with a nuclear green dye (methyl
green). (D) Femurs treated with vehicle alone (veh.) or (E) E2 were immunostained for FasL (red) and RUNX2 (green) and counterstained with
DAPI (blue).
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apoptosis
To conﬁrm that osteoblasts are required for estrogen-induced
apoptosis of human osteoclasts, antibody-puriﬁed monocytes
from peripheral blood obtained from blood donors were used
to produce osteoclasts. Large, multinucleated, TRAP-positive
cells formed in the presence of RANKL and M-CSF after 8
days (Figure 7A). Alkaline phosphatase-positive osteoblasts
could not be detected in these cultures. When 10nM E2 was
added to the culture media, during the entire course of
differentiation no apoptosis occurred, and osteoclasts differ-
entiated into equivalent numbers of large-multinucleated,
TRAP-positive cells (Figure 7A).
A co-culture system was established to demonstrate the
dependence on osteoblasts for the induction of apoptosis in
human osteoclasts. MC3T3 osteoblast cells were incubated
for 8 days in the presence of puriﬁed human monocytes. In
the absence of E2, fully differentiated osteoclasts formed in
the presence of MC3T3 osteoblasts (Figure 7B, left panel).
When 10nM E2 was added to the co-culture during the entire
course of differentiation, there were fewer multinucleated,
TRAP-positive cells and the TRAP-positive cells were smaller
in diameter and had fewer nuclei per cell (Figure 7B, right
panel). Quantiﬁcation of the number of multinucleated cells
in each condition shows that only in the presence of osteo-
blasts there is an E2-mediated decrease in osteoclast number
(Figure 7C). These results demonstrate that osteoblasts are
required for the E2 induction of osteoclast cell death.
To demonstrate that expression of ERa in osteoblasts is
sufﬁcient to induce apoptosis of osteoclasts, MC3T3 cells
Figure 6 Apoptosis of pre-osteoclasts is mediated by ERa.( A) Pre-osteoclasts were differentiated with M-CSFand RANKL for 6 days and then
treated for 16h with vehicle control (ethanol, EtOH), 1nM E2 and/or 10nM ICI 182,780 (ICI). Cells were ﬁxed and apoptosis was detected by
TUNEL. Quantiﬁcation was performed with a laser scanning cytometer (LSC). (B) Bone marrow cells from wild-type (WT), ERaKO or ERbKO
mice were differentiated with M-CSF and RANKL in the presence or absence of 10nM E2 to the pre-osteoclast stage. Cells were then ﬁxed and
apoptosis was detected by TUNEL. Quantiﬁcation was performed with a laser scanning cytometer (LSC). (C) Bone marrow cells from wild-type
(WT), ERaKO or ERbKO mice were differentiated with M-CSF and RANKL in the presence or absence of 10nM E2 for 8 days. Cells were then
ﬁxed and stained for TRAP. Multinucleated cells, deﬁned as cells that are TRAP positive and containing three or more nuclei, were counted in
each well. Three wells were counted for each genotype. (D) Bone marrow cells from wild-type and ERaKO mice were cultured in mesenchymal
stem cell media and then differentiated under osteoblastic conditions for 9 days. mRNA for FasL was measured by quantitative PCR. (E) U20S-
ERb cells were deprived of estrogen for 3 days in phenol red-free media containing 5% CDT-FBS. They were then treated with 10nM E2 for 3h
and RNA was obtained. FasL and Rbbp1 mRNA levels were analyzed by quantitative PCR. (F) U20S-ERb cells were deprived of estrogen for 3
days in phenol red-free media containing 5% CDT-FBS. They were then treated with 10nM E2 for 45min. An anti-Flag antibody was used to
immunoprecipitate ERb and quantitative PCR was performed to detect the Rbbp1 enhancer or the FasL enhancer (þ86kb site). Each PCR was
normalized to input.
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marrow under osteoclast growth conditions that we
previously showed contains a minority of osteoblasts as
well. The number of wild-type TRAP-positive, multinucleated
osteoclasts decreased in the presence of E2 with or without
the addition of MC3T3 cells (Figure 7D). In contrast, the
number of mature osteoclasts from ERaKO mice decreased
only in the presence of MC3T3 osteoblasts and E2
(Figure 7D). To conﬁrm that apoptosis was responsible for
the reduction in mature osteoclast numbers, TUNEL assays
were performed in parallel. Bone marrow-derived wild-type
osteoclasts were TUNEL positive in the presence of E2, with
or without MC3T3 osteoblasts (Figure 7E and Supplementary
Figure 8). In striking contrast, ERaKO-derived osteoclasts
underwent E2-mediated apoptosis only in the presence of
MC3T3 osteoblasts (Figure 7E and Supplementary Figure 8).
These results conﬁrm that expression of ERa in osteoblasts is
sufﬁcient to induce estrogen-stimulated apoptosis of osteo-
clasts.
SERMs also upregulate FasL in osteoblasts to induce
apoptosis
As SERMs are clinically important in the treatment of osteo-
porosis, we sought to determine if SERMs could induce
apoptosis by the same mechanism as E2. Bone marrow
cultures were treated with either 4-hydroxytamoxifen (tam)
or raloxifene (ral). Following treatment with either SERM,
nearly 100% of pre-osteoclasts were apoptotic after 16h
(Figure 8A).
To determine if tam and ral upregulate FasL by the same
mechanism as does E2, ChIP was performed after treating
U20S-ERa cells with tam or ral for 45min. Both tam and ral
lead to the recruitment of ERa to the FasL enhancer
(Figure 8B) to a similar extent as E2 (Figure 3C).
Furthermore, quantitative PCR showed that tam and ral are
each capable of inducing FasL mRNA (Figure 8C). These data
taken together suggest that tam and ral are capable of
inducing apoptosis in pre-osteoclasts via upregulation of
FasL in osteoblasts.
Figure 7 Osteoblasts are required for estrogen-mediated apoptosis. (A) Human monocytes were differentiated with M-CSF and RANKL to
osteoclasts, without or (B) with osteoblasts (MC3T3 cells), and (left) without or (right) with 10nM E2 for 8 days. The cells were then ﬁxed and
stained for TRAP. (C) The number of multinucleated cells per ﬁeld from (A) and (B) was counted and expressed as a percentage of the vehicle
control-treated cells. Each treatment was counted in triplicate and error bars represent 71 s.d. (D) Bone marrow cells from wild-type or ERaKO
mice were co-cultured with or without MC3T3 cells and without or with 10nM E2 under osteoclastic conditions for 8 days. The cells were then
ﬁxed and stained for TRAP. The number of multinucleated cells per ﬁeld was counted and expressed as a percentage of the vehicle control-
treated cells. (E) Cells were cultured as in part D, except that 10nM E2 was added at day 6 for 16h. The cells were then ﬁxed and apoptosis was
detected by TUNEL. Quantiﬁcation was performed with a laser scanning cytometer.
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An understanding of the mechanism of protective effects of
estrogen and SERMs in bone has very important implications
for the prevention and treatment of osteoporosis. Previous
work by others has shown that a signiﬁcant part of this effect
comes from the ability of estrogen to induce osteoclast
apoptosis. Recent work from Nakamura et al (2007) suggests
a direct role of ERa in osteoclasts and that estrogen-induced
apoptosis of osteoclasts involves FasL-mediated cell suicide.
We have explored the mechanistic basis for the ability of
estrogen to induce osteoclast apoptosis and in contrast to the
ﬁndings of Nakamura and colleagues we ﬁnd a critical role of
osteoblasts in FasL-mediated killing of pre-osteoclasts. In
cell culture and in vivo, we ﬁnd that estrogen induces
FasL expression in osteoblasts and not in osteoclasts.
Furthermore, antibody-puriﬁed osteoclasts do not undergo
estrogen-induced apoptosis unless osteoblasts are added in a
co-culture system. Furthermore, co-cultures of osteoblasts
and ERaKO bone marrow-derived osteoclasts demonstrate
that ERa in osteoblasts is sufﬁcient for osteoclast apoptosis.
In addition, we have identiﬁed a cell-type-speciﬁc estrogen-
regulated enhancer some 86kb downstream of the FasL
coding region that is active in osteoblasts, conﬁrming the
direct regulation of FasL by ERa in this cell type.
Bone remodeling is a complex interaction between many
cell types; osteoblasts and osteoclasts are regulated both by
each other and by cells in the bone marrow, such as T cells
and dendritic cells (Clowes et al, 2005). Osteoblasts and bone
marrow stromal cells express both RANKL, to differentiate
osteoclasts, and osteoprotegerin, to inhibit osteoclast differ-
entiation. Furthermore, bidirectional signaling between
osteoclasts and osteoblasts has been described for ephrins
and ephrin receptors, illustrating the importance of cell-to-
cell cross talk in the regulation of osteoblast and osteoclast
differentiation and survival (Zhao et al, 2006).
The etiology of osteoporosis is multifactorial, including a
genetic component. Between 50 and 85% of bone mass is
thought to be genetically determined (Ralston and de
Crombrugghe, 2006). To date, no studies on the role of Fas
or FasL polymorphisms or mutations in osteoporosis have
been done. However, Fas mutant mice (lpr mice) and FasL
mutant mice (gld mice) have an increase in the number of
osteoclasts and a decrease in bone mineral density (Wu et al,
2003). We have demonstrated that pre-osteoclasts from gld
and lpr mice fail to undergo estrogen-induced apoptosis,
which would lead to the observed phenotype of these mice.
In addition, while post-menopausal estrogen levels and poly-
morphisms in ERa have been linked to the risk of osteo-
porosis, no studies to date have explored the possibility
of polymorphisms in the cis-regulatory targets of ERa. The
identiﬁcation of the ERa-dependent enhancer of FasL sug-
gests a possible site to explore as a cause of phenotypic
variation in the population with regard to osteoporosis risk.
Estrogen deﬁciency has been associated with an increase
in cytokines that enhance osteoclast differentiation. There is
a complex balance between the immune system, osteoblasts
and osteoclasts, and estrogen regulates many of these reg-
ulatory factors. These cytokines include IL-1, IL-6, M-CSF,
RANKL and TNF-a (reviewed in Zallone, 2006). A change in
these cytokines may prime the pre-osteoclast for estrogen-
mediated apoptosis by FasL and explain the requirement for
ERa expression in osteoclasts, as suggested by Nakamura
et al. Further studies exploring the direct ERa-dependent
targets in osteoclasts should help shed light on the cell-
autonomous role of estrogen in this cell type.
In conclusion, these experiments identify a critical para-
crine signal emanating from osteoblasts that plays an impor-
tant role in the protective effects of estrogen in bone. The
ﬁnding that existing SERMs such as tam and ral that have
beneﬁcial effects on bone exploit the same mechanism
should facilitate the development of new therapies that retain
Figure 8 SERMs regulate FasL to induce apoptosis. (A) Pre-osteo-
clasts were differentiated with M-CSF and RANKL and then treated
for 16h with vehicle (EtOH), 1mM tam or 10nM ral. Cells were ﬁxed
and apoptosis was detected by TUNEL. Data are representative of
three independent experiments. (B) U20S-ERa cells were deprived
of estrogen for 3 days in phenol red-free media containing 5% CDT-
FBS. Cells were then treated for 45min with 1mM tam or 10nM ral.
ChIP was performed with an antibody to ERa and quantitative PCR
was performed to detect the FasL enhancer (þ86kb site). Each PCR
was normalized to input. (C) Cells were deprived of estrogen as in
part B. They were then treated with 1mM tam or 10nM ral for 3h
and RNA was obtained. FasL mRNA was analyzed by quantitative
PCR. Error bars represent 71s . d .
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effects of existing SERMs.
Materials and methods
Reagents
E2, tam and doxycycline were purchased from Sigma-Aldrich Co.
ICI 182,780 was generously provided by Astra-Zeneca. Charcoal-
dextran-treated fetal bovine serum (CDT-FBS) was purchased from
Omega Scientiﬁc. RANKL and M-CSF were purchased from R&D
Systems. TRAP and alkaline phosphatase stains were obtained from
Takara Bio Inc. The following antibodies were used: FasL (Santa
Cruz Biotechnology Inc., N-20; and R&D Systems, 101626), Fas
(Santa Cruz Biotechnology Inc., A-20), RUNX2 (R&D Systems,
232902), ERa (Santa Cruz Biotechnology Inc., HC-20; and Lab
Vision Corporation, Ab-10), RNA polymerase II (Abcam, 8WG16)
and Flag (Sigma-Aldrich Co., M2). Goat anti-rabbit Alexa 488,
donkey anti-goat Alexa 488 and goat anti-rabbit Alexa 594 were
purchased from Invitrogen Corporation.
Animals
All animal work was approved by the Animal Care and Use
Committee at Dana-Farber Cancer Institute. Seven-week-old male
BALB/c mice were obtained from Charles River Laboratories Inc.
No difference in apoptosis was observed between male and female
mice (Kousteni et al, 2002), but male mice were used consistently
for in vitro experiments. ERa,E R b and ERab knockout mice were
kindly provided by Dr Pierre Chambon (Dupont et al, 2000). Wild-
type (C57BL/6) littermates were used as controls. FasL knockout
mice (B6Smn.C3-Faslgld/J) were obtained from Jackson Labora-
tories, along with age-matched wild-type controls (C57BL/6Smn).
Fas knockout mice (C3.MRL-Fas
lpr/J) were also obtained from
Jackson Laboratories, along with age-matched wild-type controls.
Ovariectomy and in vivo estrogen treatment
Six-week-old sham or ovariectomized BALB/c mice were purchased
from Charles River. Two weeks after surgery, the mice were injected
intraperitoneally with 50mg/kg body weight of E2 or sesame oil (as
a vehicle control) for 24h (Kobayashi et al, 2006). The femurs were
snap frozen in 7% gelatin and 4mm sections were made using the
CryoJane tape transfer system or ﬁxed in 4% PFA, decalciﬁed and
parafﬁn embedded. TRAP staining of femurs was performed to
verify ovariectomy (Supplementary Figure 6). In addition, the
uterus was collected to verify ovariectomy and estrogen treatment.
Cell culture
MCF-7 cells and MC3T3-E1 cells were obtained from ATCC. U20S-
ERa cells and U20S-ERb cells, kindly provided by Dr Thomas
Spelsberg, were maintained as described (Monroe et al, 2003). At
24h before treatment with E2, ER expression in U20S-ERa or U20S-
ERb cells was induced by treatment with 100ng/ml doxycycline.
Osteoclast formation
Bone marrow was isolated from the femur and tibia of mice.
Osteoclasts were obtained as described (Takahashi et al, 2003).
Human osteoclasts were differentiated as follows: leukocytes were
obtained from the apheresis by-product of platelet donations at the
Kraft Family Blood Donor Center at Dana-Farber Cancer Institute,
Boston, MA. Monocytes were puriﬁed by negative selection using
the Monocyte Isolation Kit II (Miltenyi Biotec) and plated in aMEM
with 10ng/ml M-CSF and 30ng/ml RANKL for 8 days. TRAP and
alkaline phosphatase staining were performed according to the
manufacturer’s instructions.
Osteoblast differentiation
Primary osteoblasts were obtained from bone marrow mesenchy-
mal stem cells (from wild type or ERaKO) or the calvaria of wild-
type mice. Bone marrow was incubated for 5 days in mesenchymal
stem cell media (MesenCult Basal Media, StemCell Technologies
Inc.), followed by differentiation in 5mM b-glycerophosphate and
100 mg/ml ascorbic acid (mineralization medium) for 9 days.
Neonatal BALB/c calvaria were obtained 2 days after birth and
incubated for 40min in aMEM–1.0mg/ml collagenase P–1.25%
trypsin at 371C. These were washed in aMEM and transferred to
aMEM–1.0mg/ml collagenase P–1.25% trypsin for 1h at 371C
(Ducy et al, 1999). Digestion was stopped by the addition of aMEM/
10% FBS. The cells from the second digest were allowed to attach
for 48h and then differentiated in mineralization medium with
media replacement every 3 days. Differentiation was conﬁrmed by
quantiﬁcation of bone sialoprotein and osteocalcin mRNA, alkaline
phosphatase positivity and Von Kossa staining for mineralization.
MC3T3 cells were maintained in aMEM without ascorbic acid. For
differentiated cells, MC3T3 cells were allowed to reach conﬂuence
(day 0). Cells were then treated with 100mg/ml ascorbic acid for
10 days.
Co-culture of osteoclasts and osteoblasts
Hundred MC3T3 cells were plated in each well of a 96-well plate.
The following day, 100000 human monocytes (puriﬁed as described
above) or 100000 murine bone marrow cells (from wild-type or
ERaKO mice) were plated with the attached MC3T3 cells. The
monocytes and MC3T3 cells were cultured for 8 days with or
without 10nM E2 in aMEM with 10ng/ml M-CSF, 30ng/ml RANKL,
5mM b-glycerophosphate and 100mg/ml ascorbic acid, then ﬁxed
and stained for TRAP or TUNEL.
Apoptosis
Differentiated pre-osteoclast cultures were treated with E2 for
7–24h as described in each ﬁgure legend. Cells were ﬁxed with 4%
paraformaldehyde, and TUNEL assays (Roche Applied Sciences)
were performed according to the manufacturer’s instructions.
Apoptosis was quantiﬁed using a laser scanning cytometer
(CompuCyte Corporation). Cells were counterstained with DAPI
to visualize DNA. Each experiment was performed in triplicate, and
a representative experiment is shown.
FasL inhibition
Pre-osteoclasts were differentiated for 6 days in the presence of
10ng/ml M-CSF and 30ng/ml RANKL. On the sixth day, the media
were changed to 5% CDT-FBS-containing aMEM with M-CSF and
RANKL but without phenol red. After 24h, cells were treated with
or without 10nM E2, and with 5ng/ml rat anti-mouse FasL from
R&D Systems or control IgG to inhibit FasL.
RNA and real-time PCR
Total RNA was converted to cDNA using the Superscript III First
Strand Synthesis Kit according to the manufacturer’s instructions
(Invitrogen Corporation). Primer sequences are listed in Supple-
mentary Table 1. cDNAwas subjected to quantitative PCR using the
Applied Biosystems SYBR Green Mastermix. Each RNA sample was
collected in triplicate and each PCR was ampliﬁed in triplicate. Data
are presented as mean and standard deviation (s.d.).
Chromatin immunoprecipitation
Cells were hormone-deprived by culture for 3 days in phenol red-
free medium (Invitrogen Corporation) supplemented with 5% CDT-
FBS. Cells were challenged with hormone for 45min and ChIP was
performed as described (Carroll et al, 2005; Eeckhoute et al, 2006).
Each ChIP was performed in triplicate and each PCR was ampliﬁed
in triplicate (Eeckhoute et al, 2007). Data are presented as mean
and s.d.
Immunoﬂuorescence and laser scanning cytometry
Cells were ﬁxed with 4% paraformaldehyde for 30min on ice and
incubated overnight in blocking buffer (1  TBST, 3% BSA, 1%
normal goat or donkey serum, 0.2% sodium azide, 1% Triton X-
100). Primary antibodies were incubated overnight and analyzed
with a laser scanning cytometer (CompuCyte) and immunoﬂuores-
cence microscopy. Goat anti-rabbit Alexa 488, donkey anti-goat
Alexa 488 and goat anti-rabbit Alexa 594, all ‘highly crossed-
absorbed’ (Molecular Probes), were used to detect the primary
antibody. Cells were counterstained with DAPI in mounting
medium (Vector Laboratories Inc.) to identify nuclei. The UV
ﬂuorescence emission (4463nm) was used to contour DAPI-
stained nuclei with a minimum cell area of 20mm (ﬁrst pass). The
argon laser (488nm) was used to identify FITC conjugation (second
pass) and the long red ﬂuorescence emission (4650nm; third pass)
was excited by the He–Ne laser (633nm). Threshold values of 4000
were used to contour second and third pass and set to reject cell
clusters 41000mm
2. Eleven pixels were added from DAPI to
threshold to contour cytoplasmic area. For ﬂuorescence microscopy,
a Leica DM IRBE ﬂuorescent microscope using  10 and  63
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sion) was used for image acquisition. LSC analysis was performed
using WinCyte software (CompuCyte).
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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